tiprankstipranks
Dexcom (DXCM)
NASDAQ:DXCM
US Market
DXCM
Dexcom
RESEARCH TOOLSreports
Want to see DXCM full AI Analyst Report?

Dexcom (DXCM) Stock Forecast & Price Target

4,447 Followers
See the Price Targets and Ratings of:

DXCM Analyst Ratings

Strong Buy
22Ratings
Strong Buy
20 Buy
1 Hold
1 Sell
Based on 22 analysts giving stock ratings to
Dexcom
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DXCM Stock 12 Month Forecast

Average Price Target

$83.60
▲(30.67% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Dexcom in the last 3 months. The average price target is $83.60 with a high forecast of $112.00 and a low forecast of $64.00. The average price target represents a 30.67% change from the last price of $63.98.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"57":"$57","71":"$71","85":"$85","99":"$99","113":"$113"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$112.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$83.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$64.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[57,71,85,99,113],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.87,77.72615384615385,80.5823076923077,83.43846153846154,86.29461538461538,89.15076923076923,92.00692307692307,94.86307692307693,97.71923076923076,100.57538461538462,103.43153846153845,106.28769230769231,109.14384615384616,{"y":112,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.87,75.54153846153847,76.21307692307693,76.88461538461539,77.55615384615385,78.22769230769231,78.89923076923077,79.57076923076923,80.24230769230769,80.91384615384615,81.58538461538461,82.25692307692307,82.92846153846153,{"y":83.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.87,74.03384615384616,73.19769230769231,72.36153846153846,71.52538461538462,70.68923076923078,69.85307692307693,69.01692307692308,68.18076923076923,67.34461538461538,66.50846153846155,65.6723076923077,64.83615384615385,{"y":64,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":85.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.37,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.53,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.78,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.37,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.35,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.87,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$112.00Average Price Target$83.60Lowest Price Target$64.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on DXCM
Unknown Analyst
Deutsche Bank
Not Ranked
Deutsche Bank
$86
Buy
34.42%
Upside
Initiated
06/25/26
DexCom initiated with a Buy at Deutsche BankDexCom initiated with a Buy at Deutsche Bank
Piper Sandler Analyst forecast on DXCM
Matthew O'Brien
Piper Sandler
Piper Sandler
$75→$88
Buy
37.54%
Upside
Reiterated
06/15/26
DexCom price target raised to $88 from $75 at Piper SandlerDexCom price target raised to $88 from $75 at Piper Sandler
BTIG Analyst forecast on DXCM
Marie Thibault
BTIG
BTIG
$80
Buy
25.04%
Upside
Reiterated
06/15/26
Dexcom (DXCM) Gets a Buy from BTIG
TD Cowen Analyst forecast on DXCM
Josh Jennings
TD Cowen
TD Cowen
$75→$95
Buy
48.48%
Upside
Reiterated
06/10/26
TD Cowen Remains a Buy on Dexcom (DXCM)
Wells Fargo Analyst forecast on DXCM
Larry Biegelsen
Wells Fargo
Wells Fargo
$85
Buy
32.85%
Upside
Assigned
06/10/26
Dexcom (DXCM) Gets a Buy from Wells Fargo
Raymond James Analyst forecast on DXCM
Jayson Bedford
Raymond James
Raymond James
$81→$91
Buy
42.23%
Upside
Reiterated
06/08/26
DexCom price target raised to $91 from $81 at Raymond JamesDexCom price target raised to $91 from $81 at Raymond James
Mizuho Securities Analyst forecast on DXCM
Anthony Petrone
Mizuho Securities
Mizuho Securities
$75→$85
Buy
32.85%
Upside
Reiterated
06/08/26
Dexcom Earns Buy Rating as CONNECT Trial Strengthens CGM Outlook and Analyst Raises Price Target from $75 to $85
Bank of America Securities Analyst forecast on DXCM
Travis Steed
Bank of America Securities
Bank of America Securities
$80
Buy
25.04%
Upside
Reiterated
06/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pfizer (NYSE: PFE), Dexcom (NASDAQ: DXCM) and Glaukos (NYSE: GKOS)
Stifel Nicolaus Analyst forecast on DXCM
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$85→$90
Buy
40.67%
Upside
Assigned
06/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Dexcom (NASDAQ: DXCM), Fractyl Health, Inc. (NASDAQ: GUTS) and BioNTech SE (NASDAQ: BNTX)
Citi Analyst forecast on DXCM
Joanne Wuensch
Citi
Citi
$79→$84
Buy
31.29%
Upside
Reiterated
05/29/26
DexCom price target raised to $84 from $79 at CitiDexCom price target raised to $84 from $79 at Citi
Canaccord Genuity Analyst forecast on DXCM
William Plovanic
Canaccord Genuity
Canaccord Genuity
$100→$82
Buy
28.17%
Upside
Reiterated
05/19/26
DexCom price target lowered to $82 from $100 at CanaccordDexCom price target lowered to $82 from $100 at Canaccord
Barclays Analyst forecast on DXCM
Matt Miksic
Barclays
Barclays
$67→$64
Sell
0.03%
Upside
Assigned
05/18/26
Barclays Sticks to Its Sell Rating for Dexcom (DXCM)
William Blair Analyst forecast on DXCM
Steven Lichtman
William Blair
William Blair
―
Buy
―
Reiterated
05/15/26
Dexcom: Buy Rating Reaffirmed on Sustained Double-Digit Growth Outlook, Margin Expansion, and Governance Enhancements
Truist Financial Analyst forecast on DXCM
Richard Newitter
Truist Financial
Truist Financial
$57.82→
Buy
―
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (NASDAQ: AVAH), Collegium Pharmaceutical (NASDAQ: COLL) and Dexcom (NASDAQ: DXCM)
Goldman Sachs Analyst forecast on DXCM
David Roman
Goldman Sachs
Goldman Sachs
$80
Buy
25.04%
Upside
Reiterated
05/15/26
Analysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on DXCM
Unknown Analyst
Deutsche Bank
Not Ranked
Deutsche Bank
$86
Buy
34.42%
Upside
Initiated
06/25/26
DexCom initiated with a Buy at Deutsche BankDexCom initiated with a Buy at Deutsche Bank
Piper Sandler Analyst forecast on DXCM
Matthew O'Brien
Piper Sandler
Piper Sandler
$75→$88
Buy
37.54%
Upside
Reiterated
06/15/26
DexCom price target raised to $88 from $75 at Piper SandlerDexCom price target raised to $88 from $75 at Piper Sandler
BTIG Analyst forecast on DXCM
Marie Thibault
BTIG
BTIG
$80
Buy
25.04%
Upside
Reiterated
06/15/26
Dexcom (DXCM) Gets a Buy from BTIG
TD Cowen Analyst forecast on DXCM
Josh Jennings
TD Cowen
TD Cowen
$75→$95
Buy
48.48%
Upside
Reiterated
06/10/26
TD Cowen Remains a Buy on Dexcom (DXCM)
Wells Fargo Analyst forecast on DXCM
Larry Biegelsen
Wells Fargo
Wells Fargo
$85
Buy
32.85%
Upside
Assigned
06/10/26
Dexcom (DXCM) Gets a Buy from Wells Fargo
Raymond James Analyst forecast on DXCM
Jayson Bedford
Raymond James
Raymond James
$81→$91
Buy
42.23%
Upside
Reiterated
06/08/26
DexCom price target raised to $91 from $81 at Raymond JamesDexCom price target raised to $91 from $81 at Raymond James
Mizuho Securities Analyst forecast on DXCM
Anthony Petrone
Mizuho Securities
Mizuho Securities
$75→$85
Buy
32.85%
Upside
Reiterated
06/08/26
Dexcom Earns Buy Rating as CONNECT Trial Strengthens CGM Outlook and Analyst Raises Price Target from $75 to $85
Bank of America Securities Analyst forecast on DXCM
Travis Steed
Bank of America Securities
Bank of America Securities
$80
Buy
25.04%
Upside
Reiterated
06/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pfizer (NYSE: PFE), Dexcom (NASDAQ: DXCM) and Glaukos (NYSE: GKOS)
Stifel Nicolaus Analyst forecast on DXCM
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$85→$90
Buy
40.67%
Upside
Assigned
06/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Dexcom (NASDAQ: DXCM), Fractyl Health, Inc. (NASDAQ: GUTS) and BioNTech SE (NASDAQ: BNTX)
Citi Analyst forecast on DXCM
Joanne Wuensch
Citi
Citi
$79→$84
Buy
31.29%
Upside
Reiterated
05/29/26
DexCom price target raised to $84 from $79 at CitiDexCom price target raised to $84 from $79 at Citi
Canaccord Genuity Analyst forecast on DXCM
William Plovanic
Canaccord Genuity
Canaccord Genuity
$100→$82
Buy
28.17%
Upside
Reiterated
05/19/26
DexCom price target lowered to $82 from $100 at CanaccordDexCom price target lowered to $82 from $100 at Canaccord
Barclays Analyst forecast on DXCM
Matt Miksic
Barclays
Barclays
$67→$64
Sell
0.03%
Upside
Assigned
05/18/26
Barclays Sticks to Its Sell Rating for Dexcom (DXCM)
William Blair Analyst forecast on DXCM
Steven Lichtman
William Blair
William Blair
―
Buy
―
Reiterated
05/15/26
Dexcom: Buy Rating Reaffirmed on Sustained Double-Digit Growth Outlook, Margin Expansion, and Governance Enhancements
Truist Financial Analyst forecast on DXCM
Richard Newitter
Truist Financial
Truist Financial
$57.82→
Buy
―
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (NASDAQ: AVAH), Collegium Pharmaceutical (NASDAQ: COLL) and Dexcom (NASDAQ: DXCM)
Goldman Sachs Analyst forecast on DXCM
David Roman
Goldman Sachs
Goldman Sachs
$80
Buy
25.04%
Upside
Reiterated
05/15/26
Analysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dexcom

3 Months
Mike KratkyLeerink Partners
Success Rate
12/18 ratings generated profit
67%
Average Return
+3.93%
Copying Mike Kratky's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.93% per trade.
1 Year
Steven LichtmanWilliam Blair
Success Rate
34/49 ratings generated profit
69%
Average Return
+35.99%
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 69.39% of your transactions generating a profit, with an average return of +35.99% per trade.
2 Years
Steven LichtmanWilliam Blair
Success Rate
35/49 ratings generated profit
71%
Average Return
+83.46%
Copying Steven Lichtman's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +83.46% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DXCM Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
2
2
4
3
Buy
40
34
28
41
50
Hold
2
2
1
1
1
Sell
2
2
1
2
2
Strong Sell
0
0
0
0
0
total
45
40
32
48
56
In the current month, DXCM has received 53 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. DXCM average Analyst price target in the past 3 months is 83.60.
Each month's total comprises the sum of three months' worth of ratings.

DXCM Financial Forecast

DXCM Earnings Forecast

Next quarter’s earnings estimate for DXCM is $0.61 with a range of $0.55 to $0.66. The previous quarter’s EPS was $0.56. DXCM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.
Next quarter’s earnings estimate for DXCM is $0.61 with a range of $0.55 to $0.66. The previous quarter’s EPS was $0.56. DXCM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Sales Forecast

Next quarter’s sales forecast for DXCM is $1.29B with a range of $1.28B to $1.30B. The previous quarter’s sales results were $1.19B. DXCM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.
Next quarter’s sales forecast for DXCM is $1.29B with a range of $1.28B to $1.30B. The previous quarter’s sales results were $1.19B. DXCM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Stock Forecast FAQ

What is DXCM’s average 12-month price target, according to analysts?
Based on analyst ratings, Dexcom’s 12-month average price target is 83.60.
    What is DXCM’s upside potential, based on the analysts’ average price target?
    Dexcom has 30.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DXCM a Buy, Sell or Hold?
          Dexcom has a consensus rating of Strong Buy which is based on 20 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Dexcom’s price target?
            The average price target for Dexcom is 83.60. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $112.00 ,the lowest forecast is $64.00. The average price target represents 30.67% Increase from the current price of $63.98.
              What do analysts say about Dexcom?
              Dexcom’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of DXCM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.